BIOMAT Database Logo BIOMAT Database Logo

Treatment of malignant melanoma with methyl CCNU. 1974

R C Young, and G P Canellos, and B A Chabner, and P S Schein, and H D Brereton, and V T DeVita

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D007958 Leukocyte Count The number of WHITE BLOOD CELLS per unit volume in venous BLOOD. A differential leukocyte count measures the relative numbers of the different types of white cells. Blood Cell Count, White,Differential Leukocyte Count,Leukocyte Count, Differential,Leukocyte Number,White Blood Cell Count,Count, Differential Leukocyte,Count, Leukocyte,Counts, Differential Leukocyte,Counts, Leukocyte,Differential Leukocyte Counts,Leukocyte Counts,Leukocyte Counts, Differential,Leukocyte Numbers,Number, Leukocyte,Numbers, Leukocyte
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008297 Male Males
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009362 Neoplasm Metastasis The transfer of a neoplasm from one organ or part of the body to another remote from the primary site. Metastase,Metastasis,Metastases, Neoplasm,Metastasis, Neoplasm,Neoplasm Metastases,Metastases
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009607 Nitrosourea Compounds A class of compounds in which the core molecule is R-NO, where R is UREA. Compounds, Nitrosourea
D001830 Body Surface Area The two dimensional measure of the outer layer of the body. Area, Body Surface,Areas, Body Surface,Body Surface Areas,Surface Area, Body,Surface Areas, Body

Related Publications

R C Young, and G P Canellos, and B A Chabner, and P S Schein, and H D Brereton, and V T DeVita
Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
August 1977, Cancer treatment reports,
R C Young, and G P Canellos, and B A Chabner, and P S Schein, and H D Brereton, and V T DeVita
Methyl-CCNU in malignant melanoma--a divided dose schedule of administration.
January 1977, Oncology,
R C Young, and G P Canellos, and B A Chabner, and P S Schein, and H D Brereton, and V T DeVita
Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma.
April 1984, American journal of clinical oncology,
R C Young, and G P Canellos, and B A Chabner, and P S Schein, and H D Brereton, and V T DeVita
Nephrotoxicity of semustine (methyl-CCNU) in patients with malignant melanoma receiving adjuvant chemotherapy.
December 1981, The American journal of medicine,
R C Young, and G P Canellos, and B A Chabner, and P S Schein, and H D Brereton, and V T DeVita
Results with methyl-CCNU and DTIC in metastatic melanoma.
September 1977, Cancer,
R C Young, and G P Canellos, and B A Chabner, and P S Schein, and H D Brereton, and V T DeVita
Use of methyl-CCNU and procarbazine in advanced malignant melanoma resistant to DTIC therapy.
December 1977, Cancer treatment reports,
R C Young, and G P Canellos, and B A Chabner, and P S Schein, and H D Brereton, and V T DeVita
[Immuno-chemotherapy in patients with disseminated metastasizing stage III melanoma. Randomized study with methyl-CCNU versus C. parvum plus methyl-CCNU].
June 1978, Onkologie,
R C Young, and G P Canellos, and B A Chabner, and P S Schein, and H D Brereton, and V T DeVita
Procarbazine, vincristine, CCNU, and cyclophosphamide (POCC) in the treatment of metastatic malignant melanoma.
January 1980, Cancer treatment reports,
R C Young, and G P Canellos, and B A Chabner, and P S Schein, and H D Brereton, and V T DeVita
Clinical comparison of adriamycin and a combination of methyl-CCNU and imidazole carboxamide in disseminated malignant melanoma.
June 1976, Clinical pharmacology and therapeutics,
R C Young, and G P Canellos, and B A Chabner, and P S Schein, and H D Brereton, and V T DeVita
A phase II study of CCNU with benznidazole for metastatic malignant melanoma.
August 1986, International journal of radiation oncology, biology, physics,
Copied contents to your clipboard!